Condensed Consolidated Statements Of Stockholders' Equity - USD ($) $ in Thousands	Total	Hurdle Share Option Plan [Member]	Redeemable Noncontrolling Interests [Member]	Common Stock [Member]	Common Stock [Member] Hurdle Share Option Plan [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Hurdle Share Option Plan [Member]	Share Subscriptions Receivable [Member]	Share Subscriptions Receivable [Member] Hurdle Share Option Plan [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Other Comprehensive Income (Loss) [Member] Hurdle Share Option Plan [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Hurdle Share Option Plan [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member] Hurdle Share Option Plan [Member]	Noncontrolling Interests [Member]	Noncontrolling Interests [Member] Hurdle Share Option Plan [Member]
Beginning Balance at Dec. 31, 2020	$ 95,368			$ 13,372		$ 261,626		$ 0		$ 5,819		$ (189,995)		$ 90,822		$ 4,546
Beginning Balance, Shares at Dec. 31, 2020				114,735,712
Issuance of common shares, net of issuance costs	23,510	$ 0		$ 1,881	$ 0	162,497	$ 0	(140,868)	$ 0	0	$ 0	0	$ 0	23,510	$ 0	0	$ 0
Issuance of common shares, net of issuance costs ,Shares				15,552,688
Issuance of common shares under the Hurdle Share Option Plan (see Note 12)					7,281,376
Issuance of noncontrolling interest	885			$ 0		0		0		0		0		0		885
Stock-based compensation expense	212			0		212		0		0		0		212		0
Foreign currency translation adjustment, net of tax	(4,026)			0		0		0		(3,842)		0		(3,842)		(184)
Net income (loss)	4,044			$ 0		0		0		0		688		688		3,356
Ending Balance, Shares at Mar. 31, 2021				137,569,776
Ending Balance at Mar. 31, 2021	119,993			$ 15,253		424,335		(140,868)		1,977		(189,307)		111,390		8,603
Settlement Of Issuance Of Common Shares Value	140,868			0		0		140,868		0		0		140,868		0
Issuance of common shares, net of issuance costs	231,581			$ 2,046		229,535		0		0		0		231,581		0
Issuance of common shares, net of issuance costs ,Shares				17,250,000
Issuance of noncontrolling interest	3,649		$ 2,555	$ 0		0		0		0		0		0		3,649
Stock-based compensation expense	37,512			0		37,512		0		0		0		37,512		0
Foreign currency translation adjustment, net of tax	2,110			0		0		0		1,960		0		1,960		150
Net income (loss)	0
Net income (loss)	(50,818)		$ 2,555	$ 0		0		0		0		(48,461)		(48,461)		(2,357)
Ending Balance, Shares at Jun. 30, 2021				154,819,776
Ending Balance at Jun. 30, 2021	484,895			$ 17,299		691,382		$ 0		3,937		(237,768)		474,850		10,045
Beginning Balance at Dec. 31, 2021	385,959			$ 18,002		725,045				(8,336)		(357,803)		376,908		9,051
Beginning Balance, Shares at Dec. 31, 2021				160,677,001
Issuance of shares upon exercise of stock options, shares				42,827
Issuance of shares upon exercise of stock options	132			$ 5		127				0		0		132		0
Stock-based compensation expense	10,208			0		10,208				0		0		10,208		0
Foreign currency translation adjustment, net of tax	(4,384)			0		0				(4,373)		0		(4,373)		(11)
Net income (loss)	(37,558)			$ 0		0				0		(36,869)		(36,869)		(689)
Ending Balance, Shares at Mar. 31, 2022				160,719,828
Ending Balance at Mar. 31, 2022	354,357			$ 18,007		735,380				(12,709)		(394,672)		346,006		8,351
Beginning Balance at Dec. 31, 2021	385,959			$ 18,002		725,045				(8,336)		(357,803)		376,908		9,051
Beginning Balance, Shares at Dec. 31, 2021				160,677,001
Ending Balance, Shares at Jun. 30, 2022				161,727,785
Ending Balance at Jun. 30, 2022	320,122			$ 18,114		746,042				(21,191)		(431,290)		311,675		8,447
Beginning Balance at Mar. 31, 2022	354,357			$ 18,007		735,380				(12,709)		(394,672)		346,006		8,351
Beginning Balance, Shares at Mar. 31, 2022				160,719,828
Issuance of shares upon exercise of stock options, shares				47,957
Issuance of shares upon exercise of stock options	118			$ 6		112				0		0		118		0
Issuance of noncontrolling interest	957
Conversion of convertible notes to common stock	1,140			$ 101		1,039				0		0		1,140		0
Conversion of convertible notes to common stock, Shares				960,000
Issuance of subsidiary preferred shares	600			$ 0		0				0		0		0		600
Issuance of subsidiary preferred shares, shares				0
Issuance of subsidiary common shares	357			$ 0		0				0		0		0		357
Issuance of subsidiary common shares, Shares				0
Stock-based compensation expense	9,511			$ 0		9,511				0		0		9,511		0
Foreign currency translation adjustment, net of tax	(8,452)			0		0				(8,482)		0		(8,482)		30
Net income (loss)	0
Net income (loss)	(37,509)			$ 0		0				0		(36,618)		(36,618)		(891)
Ending Balance, Shares at Jun. 30, 2022				161,727,785
Ending Balance at Jun. 30, 2022	$ 320,122			$ 18,114		$ 746,042				$ (21,191)		$ (431,290)		$ 311,675		$ 8,447